Browse News
Filter News
Found 12 articles
-
Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates
3/27/2024
Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.
-
Amprion's αSyn Seed Amplification Assay (αS-SAA) Highlighted in 10 Presentations at AD/PD™ 2024 International Conference
3/4/2024
Amprion is pleased to announce its presence at the AD/PD™ 2024 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders in Lisbon, Portugal on March 5-9.
-
Amprion Announces Collaboration with NIH Researchers on Dementia Hallmark Study
8/23/2023
Amprion has been contracted by the National Institutes of Health Intramural Research Program's Center for Alzheimer's and Related Dementias to study the levels of misfolded alpha-synuclein proteins in people with Alzheimer's disease.
-
Amprion Announces Granting of European Patents for Seed Amplification Assay Platform
8/15/2023
Amprion, a global leader in neurodegenerative disease diagnostics, continues to fortify its Intellectual Property surrounding the company's proprietary methodology for highly sensitive detection of misfolded proteins and amyloid-like aggregates.
-
Amprion's αSynuclein Seed Amplification Assay to be Showcased at Alzheimer's Association International Conference® 2023 (AAIC®)
7/15/2023
Amprion, a global leader in the advancement of neurodegenerative disorder diagnosis, will be in attendance at the Alzheimer's Association International Conference® 2023 in Amsterdam on July 16-20.
-
Amprion Announces Presentation of Findings Related to Usage of the αSynuclein Seed Amplification Assay in Recent Parkinson's Study at 2023 AAN Annual Meeting
4/21/2023
Amprion is pleased to announce that it will attend the American Academy of Neurology (AAN) Annual Meeting in Boston April 22-27 to share insights about its SYNTap Biomarker Test, a first-in-class qualitative Laboratory Developed Test (LDT) and the only seed amplification assay available to aid physicians in diagnosing synucleinopathies.
-
MICHAEL J. FOX FOUNDATION ANNOUNCES SIGNIFICANT BREAKTHROUGH IN SEARCH FOR PARKINSON'S BIOMARKER
4/12/2023
A landmark paper published today in The Lancet Neurology journal by leaders of the Parkinson's Progression Markers Initiative (PPMI) confirms the most significant breakthrough yet in the search for a Parkinson's biomarker: a biological test for Parkinson's disease that demonstrates high diagnostic accuracy, differentiates molecular subtypes and detects disease in individuals before cardinal movement symptoms arise.
-
Amprion showcases SYNTap® Biomarker Test at AD/PD™ 2023 International Conference
3/27/2023
Amprion is pleased to announce its attendance at the AD/PD™ 2023 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders in Gothenburg, Sweden on March 28-April 1.
-
Biomarkers In Parkinson Disease Drug Development
7/15/2022
Parkinson’s disease is a most commonly diagnosed age related neurodegenerative disorder, which affects the normal movements of body due to genetic and environmental factors.
-
Up to 40% of AD patients were found to have Lewy Bodies in their brain after succumbing to the disease.
-
Amprion Joins the Fight Against Parkinson's Through Early Detection Testing
5/23/2019
Amprion today announced its proprietary technology, Protein Misfolding Cyclic Amplification (PMCA) using CSF and plasma alpha-Synuclein (αS) to aid in the diagnosis of Parkinson's disease, received a Breakthrough Device designation from U.S. FDA.
-
University of Texas Health Science Center Researchers Discover Infectious Prion Protein In Urine Of Patients With Variant Creutzfeldt-Jakob Disease
8/8/2014